Innovative Pipeline
We have advanced multiple drug candidates into late-stage clinical development and continue to progress additional drug candidates from our discovery platform.
We are one of a relatively small number of companies to have advanced a drug all the way from discovery in our own laboratories to market.
Our pipeline is focused in two primary therapy areas: cardiometabolic disease and chronic pain.
Cardiometabolic
Hypertrophic Cardiomyopathy (HCM)
HCM is a genetically driven heart condition with significant unmet need affecting nearly 20 million patients globally. Sotagliflozin is an investigational therapy in development for the treatment of both obstructive and non-obstructive HCM.
Type 1 Diabetes (T1D)
T1D is a chronic condition impacting more than 1 million adults in the U.S. Sotagliflozin (ZYNQUISTA®) is an investigational therapy in development for glycemic control alongside insulin in adults with T1D. If approved, ZYNQUISTA has the potential to be the first and only oral therapy in its class for the treatment of T1D.
Obesity
Obesity is a common, serious, and costly chronic disease impacting more than a billion people worldwide. LX9851 is an investigational drug candidate in development for the treatment of obesity and associated cardiometabolic disorders by licensee Novo Nordisk.
Chronic Pain
Diabetic Peripheral Neuropathic Pain (DPNP)
Neuropathic pain is a chronic condition with significant unmet need. It is defined as nerve pain that occurs when the nervous system malfunctions or gets damaged. Pilavapadin is an investigational therapy in development for DPNP as well as other conditions.
Milestone / Royalty Rights
We are working both independently and through collaborations and strategic alliances with third parties. These partnerships help us to capitalize on our drug target discoveries and drug discovery and development programs.
We seek to collaborate with other pharmaceutical, biotechnology, research or academic institutions with respect to:
- Drug discovery
- Development and commercialization of certain of our drug candidates, particularly in territories outside the United States or in primary care settings
- Expanding with new or complementary expertise and resources
- Capitalizing on our drug target discoveries
Explore our Products
See Products
